Hcw Biologics INC

HCW Biologics Inc. announced the pricing of a $1.6 million private placement offering, including units with common stock or pre-funded warrants and common warrants, subject to stockholder approval.

HCW Biologics Inc. announced the settlement and extinguishment of $2.8 million in disputed accounts payable, resolving legal and manufacturing cost disputes.

HCW Biologics Inc. has regained compliance with Nasdaq's Bid Price Rule and will implement a one-for-six reverse stock split to ensure continued listing.

HCW Biologics will implement a 1-for-6 reverse stock split effective June 30, 2026, to maintain Nasdaq listing compliance.

HCW Biologics announced positive preliminary human data from its Phase 1 trial of HCW9302, an IL-2 based fusion immunotherapeutic, showing encouraging results in patients with alopecia areata.

HCW Biologics Inc. announced the results of its 2026 Annual Meeting of Stockholders, where key proposals including a reverse stock split authorization and warrant repricing were approved.

HCW Biologics reported a reduced net loss for Q3 2025 but faces substantial doubt about its going concern ability, a Nasdaq compliance deadline, and ongoing legal and construction challenges.

HCW Biologics reports reduced net losses and improved equity, but faces ongoing liquidity challenges, legal disputes, and a key license suspension while advancing its immunotherapy pipeline.

HCW Biologics faces going concern doubts despite Q1 revenue increase and clinical advancements, focusing on financing and Nasdaq compliance.

HCW Biologics' Q3 2024 report reveals ongoing financial strain, strategic shifts following a legal settlement, and a focus on securing future funding.

HCW Biologics faced a challenging second quarter of 2024, marked by a significant legal settlement, a criminal fraud incident, and ongoing financial concerns, while continuing to advance its clinical programs.

HCW Biologics saw a significant increase in revenue in Q1 2024 compared to Q1 2023, but also experienced a substantial increase in net losses and ongoing concerns about its ability to continue as a going concern.

HCW Biologics Inc. reported significant losses and a material weakness in internal controls, raising substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

HCW Biologics' 10-K filing highlights advancements in its immunotherapy pipeline, strategic collaborations, and a shift towards its TRBC drug development platform for treating age-related diseases and cancer.

HCW Biologics restated its 2023 financials due to a criminal scheme that misdirected funds and raised substantial doubt about the company's ability to continue as a going concern.

HCW Biologics' 10-K filing details progress in its immunotherapy pipeline, including clinical trial updates for HCW9218 and plans for HCW9302, while also highlighting financial losses and the need for additional funding.

Hing C Wong, Chief Executive Officer, a Director and 10% owner of HCW Biologics Inc., purchased 23,210 shares of common stock on July 29, 2026 for $2.58 per share.

Lee Flowers, SVP of Business Development of HCW Biologics Inc., purchased 7,736 shares of common stock on July 29, 2026 for $2.58 per share.

Scott T Garrett, a Director of HCW Biologics Inc., purchased 7,736 shares of common stock on July 29, 2026 for $2.58 per share.

CEO Hing C. Wong acquired 113,879 shares and matching warrants in a private placement transaction.

Director Scott T. Garrett acquired 177,936 shares and matching warrants of HCW Biologics Inc. in a private placement.

HCW Biologics CFO Rebecca Byam acquired 14,235 shares and associated warrants in a private placement transaction.

HCW Biologics Inc. is holding its 2026 Annual Meeting of Stockholders on June 15, 2026, to vote on director elections, auditor ratification, a reverse stock split, and warrant proposals.

HCW Biologics Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 17, 2025, with proposals including the election of directors and ratification of the company's independent registered public accounting firm.

HCW Biologics Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

HCW Biologics files an amendment to its proxy statement to correct a clerical error regarding the number of outstanding common shares.

HCW Biologics is holding a special meeting to vote on proposals including a reverse stock split, an equity line of credit, and a note conversion to maintain its Nasdaq listing.

HCW Biologics Inc. announces its annual stockholder meeting to be held virtually on June 14, 2024, with voting open until June 13, 2024.

HCW Biologics Inc. has filed an amendment to its S-1 registration statement, primarily as an exhibits-only filing, detailing various corporate agreements and plans.

HCW Biologics Inc. has filed an S-1 registration statement for the resale of up to 5,693,950 shares of its common stock by selling stockholders.

HCW Biologics Inc. files an S-1/A to raise up to $5.6 million through a public offering of common stock or pre-funded warrants, while addressing ongoing Nasdaq listing compliance issues.

HCW Biologics Inc. has filed a registration statement for a $5.6 million offering of common stock and pre-funded warrants to fund clinical development and general corporate purposes.

HCW Biologics Inc. is offering up to 7.69 million units, each comprising common stock or pre-funded warrants and common stock warrants, aiming to raise $5 million to fund clinical development and address Nasdaq listing compliance.

HCW Biologics Inc. filed an exhibits-only amendment to its S-1 registration statement for a proposed public offering of up to $10 million in common stock and pre-funded warrants.

Dr. Hing C. Wong, Founder and CEO of HCW Biologics Inc., has significantly increased his beneficial ownership to 23.38% of the company's common stock by converting secured and unsecured notes into equity, a move aimed at strengthening the balance sheet.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, disclosing beneficial ownership of 353,680 shares, representing 4.99% of HCW Biologics Inc.'s common stock.